Intellia Therapeutics Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Investor Relations Overview Press Releases Scientific Publications & Presentations Corporate Deck Events & Presentations Press Kit Corporate Governance Financial Info Stock Info Analyst Coverage Investor Resources Intellia Therapeutics Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Jun 24, 2022 8:00 AM EDT Click Here for Webcast Supporting Materials NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial 1 MB Contact IR
Intellia Therapeutics Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Jun 24, 2022 8:00 AM EDT Click Here for Webcast Supporting Materials NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial 1 MB
